Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

US biotech startup PerturbAI has emerged from stealth with what it describes as the largest in vivo CRISPR atlas to date, a ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

A new biosensor developed at the Department of Energy's Oak Ridge National Laboratory detects the emerging presence of fungus ...

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

As reported by Reuters, the Patent Trial and Appeal Board found that Broad scientists had conceived the practical eukaryotic ...

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needsAI-driven ...

The field of plant biotechnology has quickly evolved with the advent of CRISPR-mediated gene editing, fundamentally transforming the exploration and ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% ...

CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robust underlying business along with some exposure to ...